AFT Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Hartley Atkinson

Chief Executive Officer (CEO)

NZ$931.2k

Compensación total

Porcentaje del salario del CEO	65.1%
Permanencia del CEO	26.7yrs
Participación del CEO	68.7%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	6.2yrs

Actualizaciones recientes de la dirección

Recent updates

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

Jul 30

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Jun 02

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

Mar 20

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Feb 13

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Jan 23

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Jan 02

Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

Dec 12

AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 21

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Hartley Atkinson en comparación con los beneficios de AFT Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2023	n/a	n/a	NZ$11m
Jun 30 2023	n/a	n/a	NZ$11m
Mar 31 2023	NZ$931k	NZ$606k	NZ$11m
Dec 31 2022	n/a	n/a	NZ$14m
Sep 30 2022	n/a	n/a	NZ$17m
Jun 30 2022	n/a	n/a	NZ$18m
Mar 31 2022	NZ$840k	NZ$578k	NZ$20m
Dec 31 2021	n/a	n/a	NZ$15m
Sep 30 2021	n/a	n/a	NZ$11m
Jun 30 2021	n/a	n/a	NZ$9m
Mar 31 2021	NZ$701k	NZ$506k	NZ$8m
Dec 31 2020	n/a	n/a	NZ$5m
Sep 30 2020	n/a	n/a	NZ$3m
Jun 30 2020	n/a	n/a	NZ$7m
Mar 31 2020	NZ$592k	NZ$443k	NZ$12m
Dec 31 2019	n/a	n/a	NZ$11m
Sep 30 2019	n/a	n/a	NZ$11m
Jun 30 2019	n/a	n/a	NZ$4m
Mar 31 2019	NZ$556k	NZ$431k	-NZ$3m
Dec 31 2018	n/a	n/a	-NZ$7m
Sep 30 2018	n/a	n/a	-NZ$11m
Jun 30 2018	n/a	n/a	-NZ$12m
Mar 31 2018	NZ$514k	NZ$429k	-NZ$14m

Compensación vs. Mercado: La compensación total ($USD552.36K) de Hartley está en línea con el promedio de empresas de tamaño similar en el mercado NZ ($USD574.88K).

Compensación vs. Ingresos: La compensación de Hartley ha sido consistente con los resultados de la empresa en el último año.

CEO

Hartley Atkinson

26.7yrs

Permanencia

NZ$931,219

Compensación

Dr. Hartley Atkinson, M.Pharm (Dist), PhD, is Co-Founder of AFT Pharmaceuticals Limited in 1997. Dr. Atkinson is Chief Executive Officer of AFT Pharmaceuticals Limited since September 04, 1997 and also ser...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Hartley Atkinson	Co-Founder	26.7yrs	NZ$931.22k	68.69% NZ$ 216.1m
Marree Atkinson	Co-Founder	11.7yrs	NZ$160.92k	sin datos
Theodore Witek	Independent Non-Executive Director	3.4yrs	NZ$144.81k	sin datos
David Flacks	Independent Chairman	8.9yrs	NZ$137.50k	0.17% NZ$ 536.3k
Andrew Lane	Independent Non-Executive Director	less than a year	sin datos	sin datos
Anita Baldauf	Independent Non-Executive Director	3.5yrs	NZ$75.00k	sin datos

6.2yrs

Permanencia media

Junta con experiencia: La junta directiva de AFT se considera experimentada (6.1 años de antigüedad promedio).

AFT Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

AFT Pharmaceuticals Announces Board Changes

Independent Non-Executive Director recently sold NZ$109k worth of stock

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Dr. Doug Wilson to Step Down from AFT Pharmaceuticals Board

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 05, 2022

Independent Director recently bought NZ$66k worth of stock

Recent updates

AFT Pharmaceuticals Limited to Report Fiscal Year 2024 Results on May 23, 2024

Price target decreased by 22% to NZ$3.70

Consensus EPS estimates fall by 12%, revenue upgraded

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2024

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited to Report First Half, 2024 Results on Nov 23, 2023

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Announces Board Changes

Independent Non-Executive Director recently sold NZ$109k worth of stock

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Consensus EPS estimates fall by 17%

Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year Ending March 2024

AFT Pharmaceuticals Limited to Report Fiscal Year 2023 Results on May 22, 2023

Price target decreased to NZ$4.22

Consensus forecasts updated

First half 2023 earnings released: EPS: NZ$0.01 (vs NZ$0.04 in 1H 2022)

Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?

Price target decreased to NZ$5.51

AFT Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 24, 2022

AFT Pharmaceuticals Limited Update on Maxigesic IV Us Registration Filing

AFT Pharmaceuticals Limited Completes Pascomer Clinical Study

Dr. Doug Wilson to Step Down from AFT Pharmaceuticals Board

US FDA Seeks More Information on AFT Pharmaceuticals Limited's Maxigesic IV Application

Price target decreased to NZ$4.40

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 05, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?

Investor sentiment improved over the past week

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year to 31 March 2023

AFT Pharmaceuticals Limited to Report Fiscal Year 2022 Results on May 23, 2022

Price target increased to NZ$5.88

AFT Pharmaceuticals Announces US Food and Drug Administration Approve Topical Treatment Indicated for Facial Angiofibroma

Independent Director recently bought NZ$66k worth of stock

Independent Director recently bought NZ$171k worth of stock

AFT Pharmaceuticals Limited Welcomes Australian Federal Court Appeal Success

Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?

First half 2022 earnings released: EPS NZ$0.04 (vs NZ$0.01 in 1H 2021)

Price target increased to NZ$5.88

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

AFT Pharmaceuticals Got First Regulatory Approval of Maxigesic Oral Liquid in Europe

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Full year 2021 earnings released

AFT Pharmaceuticals Limited Announces Earnings Guidance for the Fiscal Year 2022

CFO & Company Secretary exercised options to buy NZ$205k worth of stock.

Consensus EPS estimates fall to NZ$0.092

Price target decreased to NZ$4.95

AFT Pharmaceuticals Revises Earnings Guidance for the Year to 31 March 2021

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

AFT Pharmaceuticals Signs an Exclusive Maxigesic IV Licensing Agreement for Eight New European Markets

New 90-day low: NZ$4.21

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

New 90-day high: NZ$5.51

AFT Pharmaceuticals Limited Appoints Anita Baldauf as Non-Executive Director

New 90-day low: NZ$4.55

Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

Analysts lower EPS estimates to NZ$0.11

AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Revenue and earnings miss expectations

AFT Pharmaceuticals Limited Appoints Eddie Townslie as the Local Director of AFT Pharmaceuticals Europe

New 90-day high: NZ$5.46

AFT Pharmaceuticals Receives a US Food and Drug Administration Complete Response Letter Covering Its Application for the Approval of A Tablet Version of Its Maxigesic® Pain Relief Medication

AFT Pharmaceuticals Limited and Setek Sign Supply Agreement

AFT Pharmaceuticals Limited Appoints Anita Baldauf as a Non-Executive Director

AFT Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 19, 2020